ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2022
Tumor Cells Modulate Macrophage Phenotype in a Novel In Vitro Co-Culture Model of the NSCLC Tumor Microenvironment.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- A zinc organic metal skeleton vaccine for lung cancer treatment can stimulate strong innate and adaptive anti-tumor immunity.Materials today. Bio · 2026Article
- [Standardized Construction of Lung Cancer Organoids and Their Application Progress in the Precise Treatment of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Preoperative monocyte-to-albumin ratio predicts overall survival after hepatectomy for hepatocellular carcinoma: a single-center retrospective study.World journal of surgical oncology · 2026Article
- Defining the tumor microenvironment of non-small cell lung cancer.Immunology and cell biology · 2026Review
- Exploring macrophage polarization: biological insights, key laboratory techniques and research perspectives.Frontiers in immunology · 2026Review
- Therapeutic mRNA vaccines for lung cancer: reshaping the tumor microenvironment to enhance anti-tumor immunity.Frontiers in immunology · 2026Review
- Amino acids metabolism: a potential target for cancer treatment.Molecular cancer · 2025Review
- Article
- Tumoural Hypoxic Extracellular Vesicles Foster a Protective Microenvironment in Triple-Negative Breast Cancer.Journal of extracellular biology · 2025Article
- Immunosenescence and cancer: molecular hallmarks, tumor microenvironment remodeling, and age-specific immunotherapy challenges.Journal of hematology & oncology · 2025Review
- The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer.Cancers · 2025Review
- M2 macrophage-derived exosomes promote cell proliferation, migration and EMT of non-small cell lung cancer by secreting miR-155-5p.Molecular and cellular biochemistry · 2025Article
- Multiple-omics analysis reveals a dedifferentiation-immune loop in intrahepatic cholangiocarcinoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Gold and Silver Nanoparticles Efficiently Modulate the Crosstalk Between Macrophages and Cancer Cells.International journal of nanomedicine · 2025Article
- NOS2/ARG1 axis and immune cell ratios as promising prognostic and predictive biomarkers for Cetuximab combined with chemotherapy in wt-KRAS human colorectal cancer.Frontiers in immunology · 2025Article
- Inhibition of Proteasome LMP2 Activity SuppressesOncology research · 2025Article
- Co-culture system of breast cancer and normal cells to investigate inflammation: using doxorubicin encapsulated in adipose-derived exosomes.Medical oncology (Northwood, London, England) · 2024Article
- Integrative analysis of aging-related genes reveals CEBPA as a novel therapeutic target in non-small cell lung cancer.Cancer cell international · 2024Article
- Microglia-mediated drug substance transfer promotes chemoresistance in brain tumors: insights from an in vitro co-culture model using GCV/Tk prodrug system.Cancer cell international · 2024Article
- PRKDC regulates cGAMP to enhance immune response in lung cancer treatment.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
introductionMacrophage phenotype in the tumor microenvironment correlates with prognosis in NSCLC. Immunosuppressive macrophages promote tumor progression, whereas proinflammatory macrophages may drive an antitumor immune response. How individual NSCLCs affect macrophage phenotype is a major knowledge gap.
methodsTo systematically study the impact of lung cancer cells on macrophage phenotypes, we developed an in vitro co-culture model that consisted of molecularly and clinically annotated patient-derived NSCLC lines, human cancer-associated fibroblasts, and murine macrophages. Induced macrophage phenotype was studied through quantitative real-time polymerase chain reaction and validated in vivo using NSCLC xenografts through quantitative immunohistochemistry and clinically with The Cancer Genome Atlas (TCGA)-"matched" patient tumors.
resultsA total of 72 NSCLC cell lines were studied. The most frequent highly induced macrophage-related gene was Arginase-1, reflecting an immunosuppressive M2-like phenotype. This was independent of multiple clinicopathologic factors, which also did not affect M2:M1 ratios in matched TCGA samples. In vivo, xenograft tumors established from high Arginase-1-inducing lines (Arg
conclusionsIn our in vitro co-culture model, a large panel of patient-derived NSCLC lines most frequently induced high-expression Arginase-1 in co-cultured mouse macrophages, independent of major clinicopathologic and oncogenotype-related factors. Arg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.